Dabigatran and postmarketing reports of bleeding

N Engl J Med. 2013 Apr 4;368(14):1272-4. doi: 10.1056/NEJMp1302834. Epub 2013 Mar 13.

Authors

Mary Ross Southworth¹, Marsha E Reichman, Ellis F Unger

Affiliation

¹ Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

PMID: 23484796
DOI: 10.1056/NEJMp1302834

No abstract available

MeSH terms

Anticoagulants / adverse effects
Antithrombins / adverse effects*
Benzimidazoles / adverse effects*
Dabigatran
Gastrointestinal Hemorrhage / chemically induced
Hemorrhage / chemically induced*
Humans
Intracranial Hemorrhages / chemically induced
Product Surveillance, Postmarketing*
Randomized Controlled Trials as Topic
United States
United States Food and Drug Administration
Warfarin / adverse effects
beta-Alanine / adverse effects
beta-Alanine / analogs & derivatives*

Substances

Anticoagulants
Antithrombins
Benzimidazoles
beta-Alanine
Warfarin
Dabigatran